Evaluation of the Protective Role of the L-DOPA Against Age Related Macular Degeneration in Parkinson's Patients
- Conditions
- Macular Degeneration, Senile
- Registration Number
- NCT02863640
- Lead Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
- Brief Summary
Age related macular degeneration (ARMD) is a major and irreversible cause of blindness among the elderly. The sub-retinal space, located between the retinal pigmentary epithelium (RPE) and the external segments of the retinal photoreceptors, plays a crucial role in this pathology. A recent epidemiologic study in the US, unpublished yet, has shown that patients treated with the L-DOPA, developed only later an ARMD when compared to the untreated patients.
The L-Dopa is an endogenous ligand of the GPR43 receptor, located on the RPE's cell's apical pole.
This receptor, via several intracellular mechanisms, regulates the cell's exosomal and endosomal pathways: it would appear that the L-DOPA, by stimulating this receptor, decreases significantly the RPE's exosome release.
The contents of the exosomes is still uncertain, however in addition to their signalization role, it seems they transport pro-inflammatory components, possibly helping the cellular recruitment due to the mononuclear phagocytic systems, particularly toxic for the photoreceptors.
The aim of this study is to validate the hypothesis stating that he L-DOPA would play a protective role against age related macular degeneration.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 13
- Patients aged of 70 years old and more
- Parkinson's disease
- Opposition to participate in this trial
- Patient under a measure of legal protection
- Absence of affiliation to social security or universal health coverage (CMU)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Diagnosis of ARMD based on ophtalmological examination combining color retinography, optical coherence tomography and fundus autofluorescence Imaging Diagnosis of ARMD made during a single consultation lasting about an hour Risk of ARMD : Ratio between the ARMD prevalence rate in patients with an elevated cumulated dose of L-DOPA and the ARMD prevalence rate in patients with a low cumulated dose of L-DOPA Risk adjusted according to age and sexe
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Fondation Ophtalmologique A. de Rotchschild
🇫🇷Paris, France
Fondation Ophtalmologique A. de Rotchschild🇫🇷Paris, France